Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

NCT03190174 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Ewing Sarcoma
PEComa
Epithelioid Sarcoma
Desmoid Tumor
Chordoma
Non Small Cell Lung Cancer
Urothelial Carcinoma
Melanoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Hepatocellular Carcinoma
Classical Hodgkin Lymphoma
Colorectal Cancer
MTOR Activating Mutation

Interventions

DRUG: Nab-Rapamycin
BIOLOGICAL: Nivolumab

Sponsor

Sarcoma Oncology Research Center, LLC

Collaborators

[object Object]